Her research initially focused on
oncovirology - the role of viruses in causing cancer, looking to develop
cancer vaccines. In her initial set of experiments, she attempted to use fragments of oncoviruses to see if they caused an
immune response in animals; as part of these experiments she used membrane fragments from tumors caused by the virus as a
scientific control. To her surprise, the membrane fragments elicited a stronger response. Colleagues and funders were skeptical, but she was able to validate her results and eventually invented methods using ultrasound to isolate the immune-inducing substance from the membrane fragments. This led to one of the first identification of
tumor antigens (also called "tumor-associated antigens"). She then turned back to virology and joined the effort to develop an
HIV vaccine. and later Neogenix (subsequently sold to Precision Biologics, Inc.), the lead product of which is
ensituximab, a
monoclonal antibody raised against a set of tumor antigens identified by Hollinshead. She served on Oncology Boards for
Medical College of Pennsylvania, and Neogenix Oncology, Inc. == Honors and awards ==